Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Price Target at $8.00

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given an average rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several equities analysts have issued reports on QNCX shares. D. Boral Capital decreased their price objective on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, March 25th. Oppenheimer initiated coverage on Quince Therapeutics in a research report on Monday, March 24th. They issued an “outperform” rating and a $10.00 target price for the company.

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors have recently added to or reduced their stakes in QNCX. Geode Capital Management LLC boosted its stake in Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after acquiring an additional 36,807 shares during the last quarter. Shay Capital LLC grew its stake in Quince Therapeutics by 60.8% in the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after purchasing an additional 104,616 shares in the last quarter. Scharf Investments LLC bought a new stake in Quince Therapeutics in the fourth quarter valued at about $170,000. Intellectus Partners LLC bought a new stake in Quince Therapeutics in the first quarter valued at about $71,000. Finally, Northern Trust Corp raised its stake in Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares in the last quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $0.99 on Friday. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a market capitalization of $43.67 million, a PE ratio of -0.80 and a beta of 0.74. The business’s fifty day moving average price is $1.31 and its 200 day moving average price is $1.48.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The firm had revenue of $0.17 million during the quarter. On average, sell-side analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.